Ipsen Accuses Government Of Backward Step With Proposed Changes to Statutory Pricing Scheme
Ipsen and other experts have criticized proposals from the UK government on changes to the statutory scheme for the pricing of branded medicines. Plans for differential rebates are seen as too complex, meaning their impact is difficult to predict and they could end up costing the government more.
You may also be interested in...
The UK’s pharmaceutical industry association, the ABPI, claims that “fundamental failures” in the government’s consultation and impact assessment for proposed changes to the branded medicines statutory pricing scheme could be grounds for legal challenge.
The pharmaceutical industry says financial uncertainties are a key reason why the English Innovative Medicines Fund (IMF) – offering the potential for time-limited funding for promising non-cancer treatments where benefits are uncertain at launch - has still not been used a year after it was put in place. Industry wants the National Health Service to share the financial risk of taking part in the fund.
Proposed changes to the UK statutory pricing scheme from 2024 would see a slight drop in the rebate rate compared with that applied to drug sales this year, but the ABPI warns that the clawbacks planned are still much too high and that the move could undermine talks on a new voluntary scheme.